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 Background: Premature atherosclerosis in HIV-infected patients is associated with chronic infection by itself and adverse ef-
fects of antiretroviral treatment (ART). Extra virgin olive oil (EVOO) has a beneficial effect on the cardiovascu-
lar system because of its anti-inflammatory properties.
  The objective of this study was to determine whether the consumption of EVOO improves inflammation and 
atherosclerosis biomarkers in HIV-infected patients receiving ART.
 Material/Methods: This randomized, crossover, controlled trial included 39 HIV-positive male participants who consumed 50 mL 
of EVOO or refined olive oil (ROO) daily. Four participants dropped out of the study. Leukocyte count, erythro-
cyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hsCRP), interleukin-6, fibrinogen, total cho-
lesterol, LDL cholesterol, HDL cholesterol, triglycerides, malondialdehyde, glutathione-peroxidase, superoxide 
dismutase, oxidized LDL and von Willebrand factor were determined before the first and after each of the 2 in-
tervention periods. Intervention and washout periods lasted for 20 and 14 days, respectively.
 Results: In participants with >90% compliance (N=30), hsCRP concentrations were lower after EVOO intervention (geo-
metric mean [GM], 1.70 mg/L; 95% confidence interval [CI], 1.15–2.52) compared to ROO administration (GM, 
2.92 mg/L; 95% CI, 1.95–4.37) (p=0.035). In participants using lopinavir/ritonavir, ESR and hsCRP concentra-
tions decreased 62% and 151%, respectively, after EVOO administration. In the whole study population (N=35) 
we found no difference in analyzed biomarkers after EVOO administration.
 Conclusions: Our exploratory study suggests that EVOO consumption could lower hsCRP in patients on ART.
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Background
Antiretroviral therapy (ART) prolongs life expectancy and im-
proves the quality of life in HIV-infected people. However, 
persons successfully treated with ART also have an increased 
risk for developing many chronic conditions (e.g., subclinical 
atherosclerosis, coronary heart disease (CHD), diabetes mel-
litus, renal disease, malignancies) [1,2]. CHD and myocardial 
infarction have been reported in relatively young HIV-infected 
patients [3] and some reports found an association between 
increased frequency of myocardial infarction and protease in-
hibitors (PI) or abacavir use [4,5]. HIV infection is a chronic in-
flammatory disease that disrupts the endothelial function. It 
is now understood that inflammation is a major component 
in the pathogenesis of atherosclerosis [6]. The adverse effects 
of ART (e.g., high levels of total cholesterol, LDL cholesterol, 
and triglycerides) could also have an additional influence on 
accelerated atherosclerosis development. Traditional risk fac-
tors such as male sex, older age, and cigarette smoking may 
contribute to the appearance of cardiovascular risks and dis-
ease in HIV-infected patients [7–10].
In the last few decades many studies have been conducted 
to analyze the influence of some potentially healthy food in-
gredients [11–13] or vitamin supplements [14] on atheroscle-
rosis biomarkers. Extra virgin olive oil (EVOO) is an ingredient 
believed for centuries to have a favorable influence on health, 
although some of its features were better defined only recent-
ly [11,12]. EVOO is the main source of dietary fats in some 
Mediterranean countries. Besides its high content of oleic 
acid, which is monounsaturated and less prone to lipid per-
oxidation, EVOO has some other important components such 
as phenolic compounds [15]. The favorable effect on systolic 
blood pressure, HDL cholesterol level, and LDL oxidation could 
be attributed to these phenolic compounds [16–18].
Interleukin-6 (IL-6) is a pro-inflammatory cytokine that is syn-
thesized during tissue damage or infection. In hepatocytes, 
IL-6 stimulates the synthesis of acute-phase proteins such as 
C-reactive protein (CRP), fibrinogen, hepcidin, and serum am-
yloid A [19]. CRP is a pentameric protein molecule whose lev-
el during acute infection may increase to 1000 times normal 
values. Therefore, its main application is for infection and ther-
apy success monitoring. However, with improved sensitivity 
of the test (e.g., high-sensitivity CRP and hsCRP) it became an 
early atherosclerosis marker [20].
Glutathione-related metabolism enzymes such as glutathione 
peroxidase (GSH-Px) and superoxide dismutase (SOD) are in-
volved in reactive oxygen species (ROS) processing, making 
them less toxic. Inadequate removal of ROS results in oxida-
tive stress and subsequent atherogenesis. GSH-Px and SOD 
are today recognized as oxidative stress biomarkers, found to 
be disturbed in cardiovascular diseases [21].
Malondialdehyde (MDA) is a final lipid peroxidation product 
involved in the atherosclerosis process, as shown in animal 
and human studies [22,23].
Several EVOO intervention studies showed that IL-6 and hsCRP 
were decreased [24], GSH-Px mRNA was expressed at high-
er levels, enzyme activity was higher [25], and lipid peroxides 
(MDA) decreased [16].
We conducted an exploratory study to examine the effect of 
EVOO on atherosclerosis biomarkers in a group of HIV-infected 
men undergoing antiretroviral therapy. The primary outcome 
measures were changes of atherosclerosis biomarkers in HIV-
infected patients on antiretroviral regimen after EVOO con-
sumption. Secondary outcome measures were changes in ath-
erosclerosis biomarkers after EVOO consumption in patients 
treated with PI and abacavir, respectively.
Material and Methods
Participants
We recruited HIV-infected men on a stable antiretroviral reg-
imen (> 6 months) and who were currently receiving 1 of the 
following combinations: 1) nucleoside/nucleotide analogue re-
verse transcriptase inhibitors (NRTI/NtRTI) + protease inhibi-
tors (PI) (N=10), 2) NRTI/NtRTI + non-nucleoside reverse tran-
scriptase inhibitors (NNRTI) (N=28), and 3) NNRTI + PI (N=1). 
The inclusion criteria for enrollment of participants were: HIV-
seropositivity, male sex (18 to 75 years of age), being treated 
with antiretroviral drugs, undetectable HIV RNA viral load for 
at least 6 months (by ultrasensitive Amplicor HIV-1 Monitor 
test, version 1.5 (Roche Diagnostics, Indianapolis, USA), and 
glucose levels within the reference range. We excluded HIV-
patients with underlying acute/chronic diseases (e.g., diabe-
tes or kidney diseases), except history of CHD. Four of the 43 
eligible patients, who initially agreed to participate, dropped 
out before the beginning of the study. Finally, 39 participants 
were included in the study and were interviewed about fam-
ily history of CHD, vitamin supplements administration, and 
side effects of ongoing therapy, and were given a 14-point 
questionnaire on Mediterranean food consumption [26,27]. 
Clinical examination was performed by doctors and nurses in 
the Outpatient Department for HIV-infection at the University 
Hospital for Infectious Diseases. The study was approved by 
the local institutional Ethics Committee and all participants 
provided written informed consent.
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Study design
This study was registered at ClinicalTrials.gov with ClinicalTrials.
gov Identifier: NCT00925795. A single-blind, randomized, cross-
over, controlled study was conducted between September 
2009 and October 2010. Randomization of participants into 
2 groups was computer-generated by the principal investiga-
tor. Each group consumed EVOO and refined olive oil (ROO) 
as a placebo, but in different order (Sequence 1: first EVOO; 
then ROO. Sequence 2: first ROO, then EVOO). Original manu-
facturers` declarations were removed from both types of ol-
ive oils and EVOO was designated as oil number 1 and ROO as 
oil number 2. Intervention periods for oil administration last-
ed 20 days each, with 14 days of interruption (washout peri-
od) modeled on similar studies [24]. Daily doses of both oils 
were 50 mL. Participants received detailed instructions about 
olive oil consumption. It was emphasized not to cook olive oil, 
but to pour it over meals. During the washout period, partici-
pants were requested to avoid consumption of olives and ol-
ive oils of any kind. Compliance with oil consumption was as-
sessed by participant self-report after each intervention period 
and registered on a visual analogue scale with percentage ex-
pression. Participants who self-administered more than 90% 
of the whole amount of a particular olive oil in 1 sequence 
were considered compliant.
Laboratory analysis
Before the study, we analyzed a total phenolic content of sev-
eral different olive oils by the Folin-Ciocalteu method [28], 
as previously described. We decided to use EVOO and ROO, 
which contained 236 and 57 mg, respectively, of phenolic 
compounds per kilogram of oil. EVOO and ROO were origi-
nally provided from our market in large amounts. We did not 
open the bottles and just removed their original labels. Both 
types of oils were in dark bottles. Before the first, and af-
ter both intervention periods, we collected a blood sample 
in fasting state from all participants. In all 3 samples taken 
from each participant, we performed laboratory analysis for 
parameters as follows. Erythrocyte sedimentation rate (ESR), 
was measured by Westergren method, white blood cell count 
was measured on a Beckman Coulter LH 750 hematology an-
alyzer (Beckman Coulter, Inc, Brea, California, USA) as a part 
of complete blood count (CBC). HsCRP concentration was 
measured by CardioPhase® Siemens using particle-enhanced 
immunonephelometry on BN ProSpec System® instrument 
(Siemens Healthcare Diagnostics Products GmbH, Marburg, 
Germany). Interleukin-6 (IL-6) concentration was measured by 
ELISA Quantikine test (R&D Systems Europe, Abingdon, Great 
Britain). Oxidized LDL (ox-LDL), was measured by ELISA test 
(DRG Diagnostics GmbH, Marburg, Germany) and malondialde-
hyde (MDA) was analyzed by the modified thiobarbituric acid 
reactive substances (TBARS) method originally described by 
Yagi [29]. Catalytic concentrations of glutathione peroxidase 
(GSH-Px) and superoxide dismutase (SOD) were measured in 
lysate of erythrocytes prepared by centrifuging EDTA blood on 
2350 g/10 min, washing erythrocyte pellet with saline, and cen-
trifuging again at 2350 g/5 min. Lysates of erythrocytes were 
frozen at -80°C until the day of analysis. Catalytic concentra-
tion of GSH-Px was measured through glutathione oxidation-
reduction reactions by Ransel kit and catalytic concentration of 
SOD was measured by the rate of inhibition of 2-(4-iodophenyl)-
3-(4-nitrophenyl)-5-phenyltetrazolium chloride by Ransod SD 
125 kit (both kits from Randox Laboratories Ltd., Crumlin, Great 
Britain). Results for both parameters were expressed per gram 
of hemoglobin. Serum glucose level was analyzed by glucose 
oxidase method using a Fisher Diagnostics kit (Thermo Fisher 
Scientific, Middletown, Virginia, USA). Triglycerides (TG) and 
total cholesterol (TC) were measured by Thermo reagent kits 
(Electron Corporation Inc, Victoria, Australia). High-density li-
poprotein (HDL) and low-density lipoprotein (LDL) cholesterol 
were determined by standard enzymatic automated methods 
Figure 1.  Flow of participants through the trial. EVOO – extra 
virgin olive oil. ROO – refined olive oil.
Assessed for
eligibility (n=43)
Sequence 1:
19 participants
received EVOO
3 discontinued
intervention
Washout period (14 days)
Sequence 2:
20 participants
received ROO
1 discontinued
intervention
Sequence 2:
19 participants
received EVOO
35 participants
finished the study
0 discontinued
intervention
Sequence 1:
16 participants
received ROO
0 discontinued
intervention
Randomised (n=39)
4 refused to
participate
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using Herbos kits (Herbos Diagnostics, Croatia). All of the above 
biochemistry parameters were analyzed on a Beckman Coulter 
400 instrument (Beckman Coulter, Inc, Brea, California, USA). 
Fibrinogen and von Willebrand factor activity were determined 
by Multifibren®U reagent and by VWF: RCo assay (Siemens 
Healthcare Diagnostics Products GmbH, Marburg, Germany), 
respectively. All coagulation assays were measured in citrat-
ed plasma samples on a BCS XP Siemens instrument (Siemens 
Healthcare Diagnostics, Marburg, Germany).
Statistical analysis
Sample size (n=35) was determined by power analysis where 
a value was 0.05 with power (1-b) >80%. The Kolmogorov-
Smirnov test was used to assess the normality of distribution 
of investigated parameters. For non-normally distributed pa-
rameters, data were expressed as median with interquartile 
range. To determine differences in baseline characteristics of 
the 2 groups of participants, we used the Mann-Whitney test. 
Differences in laboratory parameters for subanalysis were de-
termined by Friedman test. The values P<0.05 were considered 
statistically significant.
Since this was an exploratory study, adjustments for multiple 
comparisons were not implemented. To assess the effect of 
period, treatment, and sequence, linear mixed models were 
used for statistical analysis. Values from linear mixed mod-
els are expressed as least-squares means. High-sensitivity 
CRP values were log-transformed to achieve a normal distri-
bution. The linear mixed model enabled a comparison of ath-
erosclerosis biomarkers results even in incomplete groups of 
participants (for example, participants who adhered to only 
1 olive oil). Statistical analyses were done using MedCalc 
program, version 12.1.0.0. (MedCalc Software, Mariakerke, 
Belgium) and SAS program, version 9.1.3, (SAS Institute Inc, 
Cary, North Carolina).
Variable Sequence 1 (N=19) Sequence 2 (N=20) p
Glucose (mmol/L) 5.3 (5.1–6.0) 5.7 (5.2–6.2) 0.122
Leukocyte number (×109/L) 5.4 (4.7–6.5) 5.6 (5.2–6.7) 0.339
ESR* (mm/h) 11 (6–22) 10 (6–16) 0.643
hsCRP** (mg/L) 2.14 (1.06–2.60) 1.56 (0.97–2.18) 0.703
Interleukin-6 (ng/L) 1.83 (1.22–2.17) 1.77 (1.01–2.99) 0.633
Fibrinogen (g/L) 3.3 (2.9–3.5) 3.1 (2.7–3.7) 0.757
Total cholesterol (mmol/L) 5.6 (4.7–6.5) 5.6 (5.0–6.8) 0.747
LDL cholesterol (mmol/L) 3.4 (2.5–3.9) 3.1 (2.8–4.0) 0.623
HDL cholesterol (mmol/L) 1.3 (1.1–1.3) 1.2 (1.1–1.4) 0.989
Triglycerides (mmol/L) 2.3 (1.3–3.3) 2.0 (1.6–3.1) 0.888
Malondialdehyde (μmol/L) 4.02 (3.86–5.38) 5.68 (4.11–8.01) 0.068
Glutathione peroxidase (U/g Hb) 81.6 (58.7–106.0) 82.9 (64.45–97.60) 0.822
Superoxide dismutase (U/g Hb) 1941 (1812–2073) 1745 (1747–2126) 0.369
Oxidized LDL (mg/L) 0.82 (0.57–2.89) 0.84 (0.21–3.65) 0.623
vonWillebrand factor (% of activity) 125 (83–198) 150 (130–188) 0.518
CD4+ lymphocyte number (/μL) 464 (407–584) 490 (437–692) 0.286
Puls velocity (beats/min) 82 (80–96) 80 (72–86) 0.231
Systolic blood pressure (mmHg) 125 (115–140) 125 (113–140) 0.804
Body weight (kg) 74 (69–84) 77 (73–84) 0.546
Waist circumference (cm) 86 (76–95) 90 (86–94) 0.347
Body mass index (kg/m2) 25.2 (23.3–27.9) 24.3 (23.0–26.0) 0.311
Table 1. Baseline clinical and laboratory characteristics of participants by order of olive oil administration.
Values are expressed as medians (25th–75th percentile). Sequence 1 = first Extra virgin olive oil, then Refined olive oil. 
Sequence 2 = first Refined olive oil, then Extra virgin olive oil. * Erythrocyte sedimentation rate, ** high sensitivity C-reactive protein.
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Results
Of 39 randomized participants, 35 finished the study (4 par-
ticipants did not participate in the second intervention peri-
od) (Figure 1). There were no differences in baseline clinical 
and laboratory parameters by the order of olive oil adminis-
tration (Table 1).
All participants who finished the study (N=35) had an unde-
tectable plasma HIV1-RNA viral load (<50 copies/mL) at inclu-
sion into the study. After the study (median days from inclu-
sion: 164 days, minimum 63 days, maximum 337 days), all but 
1 individual had a plasma HIV1-RNA viral load <50 copies/mL, 
and the patient with >50 copies/mL had 76 copies/mL. The 
median CD4 cell count at inclusion was 474 per µL, range 228 
to 1648 per µL. The median duration of antiretroviral therapy 
was 4.7 years, range 0.5 to 12.2 years. There were no clinical 
events during the study period, and 12 (34%) patients had a 
past history of clinical AIDS.
The median Mediterranean diet score in our participants was 5 
(interquartile range [IQR], 3–7) and was not different by sequence 
of olive oil administration (median 5 vs. 6; p=0.460). We found no 
difference in leukocyte count, ESR, hsCRP, IL-6, fibrinogen, TC, HDL 
cholesterol, TG, MDA, GSH-Px, SOD, ox-LDL, or vWf after EVOO ad-
ministration in the whole study population. There were also no 
differences after ROO intervention, except for a lower LDL choles-
terol level (p=0.020 for treatment, p=0.006 for period) (Table 2).
Thirty participants reported consuming olive oils >90% of the 
time; 27 participants were compliant to EVOO and 26 partici-
pants were compliant to ROO administration. Of those 30 indi-
viduals, 23 were compliant to both olive oils, 4 were compliant 
only to EVOO, and 3 were compliant only to ROO. In adherent 
participants (>90%), we found significantly lower hsCRP con-
centration after EVOO administration compared to hsCRP con-
centration after ROO administration (geometric mean [GM], 
1.70 mg/L; 95% confidence interval [CI], 1.15–2.52 vs. 2.92 
mg/L; 95% CI, 1.95–4.37; p=0.035) (Figure 2).
Variable
Post EVOO*
(N=35)
Post ROO**
(N=35)
Differences of least 
squares means 
p 
(treatment 
effect)
p 
(period 
effect)
p 
(sequence 
effect)
Glucose (mmol/L) 5.5 (0.1) 5.5 (0.1) –0.014 0.894 0.894 0.536
Leukocyte number (x109/L) 6.2 (0.3) 6.1 (0.3) 0.130 0.578 0.281 0.766
ESR*** (mm/h) 13 (2) 13 (2) –0.279 0.885 0.359 0.690
log hsCRP**** (mg/L) 0.23 (0.08) 0.33 (0.08) –0.097 0.298 0.204 0.624
Interleukin-6 (ng/L) 2.93 (0.54) 2.01 (0.54) 0.914 0.231 0.591 0.619
Fibrinogen (g/L) 3.3 (0.1) 3.4 (0.1) –0.083 0.569 0.868 0.402
Total cholesterol (mmol/L) 5.9 (0.2) 5.8 (0.2) 0.082 0.471 0.566 0.588
LDL cholesterol (mmol/L) 3.3 (0.1) 3.2 (0.1) 0.133 0.020 0.006 0.660
HDL cholesterol (mmol/L) 1.3 (0.0) 1.3 (0.0) 0.026 0.884 0.226 0.397
Triglycerides (mmol/L) 2.8 (0.5) 3.0 (0.5) –0.217 0.582 0.976 0.259
Malondialdehyde (μmol/L) 4.73 (0.26) 4.40 (0.26) 0.328 0.185 0.138 0.052
Glutathione peroxidase (U/g Hb) 83.0 (4.3) 84.5 (4.3) –1.521 0.455 0.043 0.443
Superoxide dismutase (U/g Hb) 1919 (37) 1965 (37) –46.941 0.125 0.571 0.717
Oxidized LDL (mg/L) 1.85 (0.39) 1.82 (0.39) 0.033 0.787 0.024 0.759
vonWillebrand factor (% of activity) 154 (12) 150 (12) 4.373 0.607 0.903 0.722
Puls velocity (beats/min) 81 (2) 80 (2) 1.393 0.464 0.249 0.945
Systolic blood pressure (mmHg) 127 (3) 130 (3) –2.860 0.208 0.971 0.565
Table 2.  Clinical and laboratory characteristics in 35 participants who finished the study after extra virgin olive oil and refined olive oil 
administration.
Values are expressed as least squares means (standard error) estimated from linear mixed model with terms for treatment, period and 
sequence. * Extra virgin olive oil; ** refined olive oil; *** erythrocyte sedimentation rate; **** high sensitivity C-reactive protein.
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When the effect of olive oil administration was analyzed in 10 
participants who received PI lopinavir/ritonavir, EVOO interven-
tion resulted in a 62% lower ESR compared to baseline values 
(median, 13; IQR, 6–19 vs. median, 21; IQR, 10–36; p=0.040). 
In the same group of participants, we observed 151% lower 
hsCRP concentrations after EVOO administration, compared to 
baseline values (median, 0.88 mg/L; IQR, 0.49–1.66 vs. medi-
an, 2.21 mg/L; IQR, 1.82–5.47; p=0.035) (Figure 3). Participants 
receiving lopinavir/ritonavir had a higher baseline fibrino-
gen concentration (median, 3.9 g/L; IQR, 3.3–4.4) than partic-
ipants treated with a NNRTI-based ART (median, 3.0 g/L; IQR, 
3.7–3.4) (p=0.004).
There were no statistically significant changes in clinical and 
laboratory parameters after olive oil administration in 11 par-
ticipants receiving abacavir.
Discussion
In this study we compared the effect of 2 different olive oils on 
atherosclerosis biomarkers in HIV-infected patients. There was 
no difference in biomarkers of atherosclerosis after consump-
tion of EVOO and ROO in the whole study population (N=35). 
However, participants with compliance >90% to at least 1 ol-
ive oil (N=30) had significantly lower hsCRP concentration af-
ter EVOO intervention, compared to ROO intervention. There 
is a possibility that the influence of phenolic compounds was 
present only in participants with high compliance to EVOO. A 
decline in hsCRP has also been observed by Fito et al. after 3 
weeks of olive oil consumption in non-HIV-infected persons [24].
After EVOO consumption, 10 patients treated with PI had sig-
nificantly lower ESR and hsCRP when compared to baseline val-
ues. Additionally, baseline values of ESR, hsCRP, interleukin-6, 
and fibrinogen were significantly increased in PI-treated par-
ticipants (N=10) when compared to non-PI-treated participants 
(N=28) (results not shown). Although a group of 10 participants 
is not sufficient to reach firm conclusions, these results sug-
gest a higher inflammation rate in PI-treated participants and 
a more significant effect of EVOO on their inflammation bio-
markers. As ART modifications are relatively frequent in our pa-
tient population [30], there was a small group of eligible pa-
tients treated for more than 6 months with PI. Of note, the only 
PI used by our participants was lopinavir/ritonavir. In 2010, the 
D.A.D. study group reported an association between myocardi-
al infarction and cumulative exposure to indinavir and lopina-
vir/ritonavir [5]. PI may increase total cholesterol and triglycer-
ide levels and decrease HDL-cholesterol levels as a consequence 
of longer action of sterol regulatory element-binding protein-1 
(SREBP-1) and protein kinase C activation [31]. However, the 
D.A.D. group authors emphasized that a higher risk of myocar-
dial infarction cannot be explained by lipid changes alone [5].
Madden et al. showed 11% higher fibrinogen concentrations 
in patients receiving PI compared to patients treated with 
NNRTI, which may be a consequence of the higher inflamma-
tion level related to PI regimen [32]. This assumption is in con-
cordance with our results.
In our participants receiving abacavir, there was no difference 
in biomarkers after both olive oil consumptions compared to 
baseline values.
Figure 2.  High-sensitivity C-reactive protein (hsCRP) values 
after extra virgin olive oil (EVOO) and refined olive 
oil (ROO) administration in a crossover study of 
30 HIV-infected patients who completed at least 1 
intervention period and had > 90% adherence. Data 
are plotted on a logarithmic scale to reduce positive 
skewness in the distributions. The geometric mean 
with 95% confidence intervals is presented (P=0.035 
for comparison of EVOO and ROO consumption).
100
10
1
0.1
P=0.035
EVOO ROO
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CR
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Figure 3.  High-sensitivity C-reactive protein (hsCRP) values at 
baseline and after extra virgin olive oil (EVOO) and 
refined olive oil (ROO) administration in a crossover 
study with a subanalysis of 10 patients receiving the 
protease inhibitor lopinavir/ritonavir. Data are plotted 
on a logarithmic scale to reduce positive skewness in 
the distributions. The horizontal line is the geometric 
mean with 95% confidence interval (P<0.05 for the 
differences in groups).
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After ROO consumption, we found lower LDL cholesterol con-
centrations than after EVOO consumption. However, this dif-
ference (3.2 vs. 3.3 mmol/L) was not high and has little clin-
ical significance.
The major clinical implication of our study is that EVOO may 
decrease the inflammation biomarkers in HIV-infected persons 
(such as hsCRP) during the 3-week period in compliant partici-
pants. Other atherosclerosis biomarkers that we analyzed (e.g., 
IL-6, ox-LDL, SOD, GSH-Px, and MDA) did not change, even in 
compliant participants. Because HIV-infected persons are im-
munocompromised, it is possible that a longer intervention pe-
riod is needed to improve atherosclerosis biomarkers, although 
this could reduce the compliance of participants.
Our study has limitations. Compliance of our participants to 
olive oil consumption relied on self-reporting. Non-compliance 
cannot be ruled out, because we did not measure metabolites 
of olive oil consumption such as tyrosol and hydroxytyrosol 
in urine [33]. We also did not measure the content of other 
olive oil ingredients that could have influenced atherosclero-
sis biomarkers (e.g., vitamin C and a-tocopherol) [34,35]. Our 
intervention periods were only 3 weeks long and it is possi-
ble that longer duration of intervention periods might have 
caused a more significant change in atherosclerotic biomark-
ers. Finally, this was only an exploratory study with a small 
number of patients.
Conclusions
Overall, we found no difference in biomarkers of inflammation 
after EVOO administration in our study population. However, 
in a subanalysis of participants with high compliance to olive 
oils, hsCRP significantly decreased after EVOO administration. 
Hence, there could be a protective effect of EVOO consumption 
on inflammatory markers in HIV-infected patients on stable 
ART, but larger studies are needed to confirm these findings.
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